FDA Investigating Data on Zithromax Z-Pak Heart Risks

Following a recent study that suggested side effects of Zithromax (azithromycin) may increase the risk of cardiovascular death, federal drug regulators have indicated that they are reviewing the potential heart risks associated with the popular antibiotic, which is also known as Z Pack, Z-Pak or Zmax. 

In a statement issued yesterday, the FDA indicated that they were aware of the Zithromax study published in the New England Journal of Medicine on May 17, which found an increased risk of death associated with 5 day Zithromax treatment when compared to amoxicillin, Cipro or no antibiotic therapy. The agency said it will communicate any new information once its review is complete.

The study was conducted by Vanderbilt University researchers, who found that patients taking Pfizer’s Zithromax (azithromycin) were 2.5 times more likely to die of a heart-related problem than those taking amoxycillin. The results of the study suggest that doctors should prescribe other antibiotics for patients who are already known to have heart problems, especially problems that affect their heart rhythms.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Zithromax Z-Pak belongs to a class of antibacterial drugs known as macrolides, which have been known to cause abnormal heart rhythm problems, including QT interval prolongation. That can lead to a fatal heart condition known as torsades de pointes. Zithromax was the only macrolide tested in the study.

The Zithromax label already carries a heart rhythm warning, after the FDA investigated all macrolides due to the problem in 2011.

The FDA has indicated that patients prescribed a Z-Pak should not stop taking their medication without speaking to their doctor, and recommended that healthcare provides be aware of the potential for QT prolongation and heart arrythmias when prescribing Zithromax or other macrolides.

Zithromax sales brought in more than $450 million for Pfizer in 2011. It is used to treat respiratory system and urinary tract infections, tonsillitis and other bacterial infections. It is also available as a generic.

1 Comments

  • CandiceMarch 3, 2014 at 3:44 pm

    I was taking this medicine last year

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted yesterday)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted yesterday)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.

Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant
Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant (Posted 2 days ago)

Following a $60 million verdict in a similar lawsuit earlier this year, trial is underway involving claims brought by an Illinois mother, whose premature daughter developed NEC from Similac, alleging that Abbott failed to warn parents and medical staff of the devastating risks associated with the cow's milk-based formula.